Cell News and Research

RSS

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Study finds molecular features responsible for the development of metastatic breast cancer

Susana Garcia-Recio, PhD, a research associate in the lab of Charles M. Perou, PhD, at UNC Lineberger Comprehensive Cancer Center, will present findings that identified molecular features responsible for the development and progression of metastatic breast cancer at the 2022 American Association for Cancer Research annual meeting. (Presentation: Abstract LB176/4, Tuesday, April 12, 3:20 p.m. ET, Room 217-219, Ernest N. Morial Convention Center in New Orleans.)

11 Apr 2022

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Yale scientists uncover key regulator of body weight. Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.

11 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

Novel strategy can shrink tumors and prolong survival in mice

A research team based at the University of Ottawa and The Ottawa Hospital has developed a virus that infects and kills cancer cells without harming normal cells, while also sending out signals to prepare nearby uninfected cancer cells for viral attack.

11 Apr 2022

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

...

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

Researchers make progress to develop a drug for treating metabolic syndrome

Metabolic syndrome increases a person's risk for diabetes, heart disease, and stroke, and includes conditions such as obesity, high blood pressure and high blood sugar.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Researchers tested whether a subunit vaccine could generate mucosal immunity in mice and prevent SARS-CoV-2 infection and related pathology.

11 Apr 2022

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

Researchers performed high-throughput evolutionary analyses of genes encoding 334 SARS-CoV-2 viral-interacting proteins of modern humans, primates, and bats.

11 Apr 2022

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

11 Apr 2022

Cell News and Research

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Study finds molecular features responsible for the development of metastatic breast cancer

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

Novel strategy can shrink tumors and prolong survival in mice

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

Chromatin accessibility as an early marker of severe COVID-19

Researchers make progress to develop a drug for treating metabolic syndrome

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

What does the Future of Microfluidics within Research Look Like?

Let’s Talk about Parkinson’s

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics